‘Regeneron’ to enter drug discovery phase 2
The company’s first phase 2 clinical trial is expected to begin in early 2017.
This is the second phase of its Phase 3 clinical trial, which is being conducted in Israel, and the first phase of the clinical trial in Europe.
“We will have a fully operational drug in 2021.
We are in the middle of our Phase 3 trial, and it’s already started,” said the company’s head of development, Dr. Michael Cohen.
The company has been pursuing Regeneron’s product development since 2007.
The company had originally proposed the idea to pharmaceutical companies, but the companies were not interested in pursuing it because it was considered too risky.
“At the time we didn’t know the success rate of Regeneron, but we were optimistic about the prospects,” said Dr. Cohen.
“When we were told that they had a 10-year failure rate, we were extremely excited and convinced that we would be successful.”
However, after receiving several offers, it was decided to go ahead with the trial and take the first steps.
“It was a tough decision, but at the end of the day we were convinced that this was the right thing to do,” said Cohen.
The team has now completed Phase 3, and they will start the Phase 4 trial, after which they will continue to refine and refine the product.
“Regenerons goal is to create the first generic medicine that can help millions of people,” said company CEO Dr. Dr. Yair Golan.
“We are committed to creating a product that can change the world.”